Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors
Brief Summary:
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with metastatic germ cell tumors that have relapsed or not responded to treatment.